Further clot circumstances tied to Johnson & Johnson COVID-19 vaccine: CDC

An official with the Facilities for Illness Management and Prevention (CDC) introduced greater than two dozen complete blood clot circumstances in people who acquired Johnson & Johnson’s one-shot COVID-19 vaccine amid a backdrop of 8.7 million recipients.

Dr. Tom Shimabukuro with the CDC COVID-19 vaccine activity pressure famous 28 complete circumstances of so-called thrombosis with thrombocytopenia (TTS) following J&J vaccination reported by way of a nationwide surveillance system, Vaccine Opposed Occasion Reporting System (VAERS). TTS is a broad time period together with the uncommon however probably lethal cerebral venous sinus thrombosis (CVST), but additionally deep vein thrombosis and pulmonary thromboembolism.

The replace marks a rise from a beforehand reported 17 cases in late April, when the company was investigating two new circumstances of a uncommon, extreme blood clot that occurred alongside low platelets in Johnson & Johnson COVID-19 vaccine recipients, along with 15 beforehand reported TTS circumstances.


The federal well being company mentioned the present proof suggests a potential causal hyperlink to the J&J COVID-19 vaccine. 

Within the replace Wednesday, Shimabukuro famous 25 so-called Tier 1 TTS circumstances (clots in uncommon, uncommon areas, just like the mind) and three so-called Tier 2 TTS circumstances (clots in widespread areas), as of Might 7. All the sufferers had been vaccinated previous to the nationwide beneficial pause on April 13, he mentioned. A lot of the sufferers had been girls, although six circumstances had been amongst males.

Extra particularly, 19 of the 28 circumstances concerned uncommon however severe blood clotting within the mind referred to as cerebral venous sinus thrombosis, or CVST. Not one of the sufferers had been pregnant, which might result in a heightened clotting danger.

Shimabukuro introduced information indicating females aged 30 to 39 had the best reporting charges of TTS at 12.4 circumstances per million doses administered, although females aged 40 to 49 had the “most pronounced” improve in circumstances; the reporting price on this age group is 9.4 clot circumstances per million doses administered.

No confirmed clotting circumstances have occurred after greater than 135 million administered doses of Pfizer’s COVID-19 vaccine, nor after over 110 million doses administered of Moderna’s jab. Officers say the mRNA vaccines will not be related to an elevated clotting danger post-vaccination.

Although greater than 1.2 million J&J doses have been administered for the reason that nationwide rollout resumed, CDC officers say the vaccines are being administered to females however in a smaller proportion.


There have been no further deaths for the reason that three reported deaths following the CDC committee’s assembly in April. Nevertheless, 4 sufferers stay hospitalized with one in intensive care, two sufferers had been discharged to a post-acute care facility and 19 sufferers had been discharged house.

The advisory committee on April 23 beneficial that the Johnson & Johnson COVID-19 vaccine resume rollout, however embrace new language on the product’s emergency use authorization (EUA) warning distant dangers of great blood clots.

Leave a Reply

Your email address will not be published. Required fields are marked *